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HerbicideL,L-Diaminopimelate aminotransferase (DapL) is an enzyme required for the biosynthesis of meso-diami-
nopimelate (m-DAP) and L-lysine (Lys) in some bacteria and photosynthetic organisms. m-DAP and Lys
are both involved in the synthesis of peptidoglycan (PG) and protein synthesis. DapL is found in speciﬁc
eubacterial and archaeal lineages, in particular in several groups of pathogenic bacteria such as Leptospira
interrogans (LiDapL), the soil/water bacterium Verrucomicrobium spinosum (VsDapL) and the alga Chla-
mydomonas reinhardtii (CrDapL). Here we present the ﬁrst comprehensive inhibition study comparing
the kinetic activity of DapL orthologs using previously active small molecule inhibitors formerly identi-
ﬁed in a screen with the DapL of Arabidopsis thaliana (AtDapL), a ﬂowering plant. Each inhibitor is derived
from one of four classes with different central structural moieties: a hydrazide, a rhodanine, a barbiturate,
or a thiobarbituate functionality. The results show that all ﬁve compounds tested were effective at inhib-
iting the DapL orthologs. LiDapL and AtDapL showed similar patterns of inhibition across the inhibitor
series, whereas the VsDapL and CrDapL inhibition patterns were different from that of LiDapL and AtDapL.
CrDapL was found to be insensitive to the hydrazide (IC50 >200 lM). VsDapL was found to be the most
sensitive to the barbiturate and thiobarbiturate containing inhibitors (IC50 5 lM). Taken together, the
data shows that the homologs have differing sensitivities to the inhibitors with IC50 values ranging from
4.7 to 250 lM. In an attempt to understand the basis for these differences the four enzymes were mod-
eled based on the known structure of AtDapL. Overall, it was found that the enzyme active sites were con-
served, although the second shell of residues close to the active site were not. We conclude from this that
the altered binding patterns seen in the inhibition studies may be a consequence of the inhibitors forming
additional interactions with residues proximal to the active site, or that the inhibitors may not act by
binding to the active site. Compounds that are speciﬁc for DapL could be potential biocides (antibiotic,
herbicide or algaecide) that are nontoxic to animals since animals do not contain the enzymes necessary
for PG or Lys synthesis. This study provides important information to expand our current understanding
of the structure/activity relationship of DapL and putative inhibitors that are potentially useful for the
design and or discovery of novel biocides.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
L,L-Diaminopimelate aminotransferase (DapL) is an enzyme re-
quired for the biosynthesis of meso-diaminopimelate (m-DAP) a
precursor of cell wall peptidoglycan (PG) and Lys. It is found in
speciﬁc eubacterial and archaeal lineages, in particular in several
groups of pathogenic bacteria, as well as many algal lineages
and plants. It is an aminotransferase catalyzing the synthesis of
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L-tetrahydrodipicolinate (L-THDP).
DapL is characteristic of one of 6 different variant pathways for
the synthesis of Lys. These pathways are divided into two main
groups. Fungi, yeast and a number of organisms that belong to
the domain archaea synthesize Lys via the intermediate a-amino-
adipate (AAA).1,2 The other pathway employs the intermediate dia-
minopimelate (DAP), which is present in most bacteria and
photosynthetic organisms.
The synthesis of Lys via the DAP pathway is subdivided into four
distinct variants: the acylase pathways, which utilize succinylated
or acetylated intermediates; themeso-diaminopimelate dehydroge-
nase (Ddh) pathway; and the L,L-diaminopimelate aminotransferase
(DapL) pathway.3–6 The synthesis of L-THDP from L-aspartate is
sharedbyall four variantsand is facilitatedby theenzymesaspartate
kinase EC 2.7.2.4 (LysC), aspartate semialdehyde dehydrogenase EC
1.2.1.11 (asd), dihydrodipicolinate synthase EC 4.2.1.52 (DapA) and
dihydrodipicolinate reductase EC 1.3.1.26 (DapB) (Fig. 1).
The feature of the DAP/Lys pathways that make them distinctive
and unique is the conversion of L-THDP to the penultimate interme-
diate m-DAP. In the acyl pathways this conversion is facilitated by
the enzymes tetrahydrodipicolinate acylase EC 2.3.1.117 (DapD),
N-acyl-2-amino-6-ketopimelate aminotransferase EC 2.6.17
(DapC), N-acyl-L,L-2,6-diaminopimelate deacylase EC 3.5.1.18
(DapE) and diaminopimelate epimerase EC 5.1.1.7 (DapF) (Fig. 1).
In the dehydrogenase pathway, L-THDP is converted to m-DAP in
a single reaction by the enzymemeso-diaminopimelate dehydroge-
nase EC 1.4.1.16 (Ddh), which circumvents the DapD, DapC, DapE
and DapF reactions in the acyl pathways. The DapD, DapC and DapE
steps are circumvented in organisms that employ the L,L-diamino-
pimelate aminotransferase EC 2.6.1.83 (DapL) pathway for Lys
anabolism. The conversion of m-DAP to Lys, catalyzed by the en-
zyme meso-diaminopimelate decarboxylase EC 4.1.1.20 (LysA) is a
common feature of all four variants (Fig. 1).
The DapL variant pathway was initially discovered by Hudson
and colleagues in 20063 through the identiﬁcation and character-
ization of a novel transaminase from the model plant ArabidopsisL-aspartate 
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Figure 1. The diaminopimelate/Lys synthesis pathways. The pathways are annotated by
(C) the L,L-diaminopimelate aminotransferase (DapL) pathway. The abbreviations deﬁniti
dehydrogenase (asd), tetrahydrodipicolinate synthase (DapA), tetrahydrodipicolinat
ketopimelate aminotransferase (DapC), N-acyl-L,L-2,6-diaminopimelate deacylase (Da
(Ddh), meso-diaminopimelate decarboxylase (LysA), L,L-diaminopimelate aminotransfera
ligase (MurE) and lysyl-tRNA synthetase (LysU).thaliana and from the cyanobacterium Synechocystis PCC6803. In
vitro analysis showed that the enzyme was capable of intercon-
verting L-THDP and L,L-DAP using in vitro analyses. In vivo analysis
showed that the enzyme was capable of functionally complement-
ing the E. coli dapD, dapE and dapD/E mutants that are auxotrophic
for both DAP and Lys.3
The rise in the number of antibiotic resistant bacteria has led to
a signiﬁcant increase in the morbidity and mortality of patients in-
fected with pathogenic bacteria, making the development and/or
discovery of novel antibiotics critical to the improvement of hu-
man health. From a bacterial point of view, the DAP/Lys pathways
are validated and attractive targets for the development of novel
antibiotics. The genomes of animals, particularly humans, do not
contain any of the genes for the synthesis of DAP/Lys from either
the AAA or DAP synthetic routes. This amino acid is deemed essen-
tial due to its overarching role in protein synthesis and must be ac-
quired by animals through dietary means. Therefore, compounds
that are speciﬁc inhibitors of the enzymes in the DAP/Lys or AAA
pathways may be nontoxic to animals.
The inhibition of DAP/Lys pathway leads to bacterial cell death,
since bacteria would not be able to synthesize PG due to the fact
that both m-DAP and Lys are involved in the cross-linking of the
PG of Gram-negative and Gram-positive bacteria, respectively7.
This cross-linking ofm-DAP and Lys into PG is facilitated by the en-
zyme UDP-N-acetylmuramoyl-L-alanyl-D-glutamate:meso-2,6-dia-
minopimelate ligase EC 6.3.2.15 (MurE). In addition, the
inhibition of Lys synthesis would lead to the inability of protein
synthesis, since Lys is one of the 20 common amino acids that
are incorporated into protein synthesis facilitated by the enzyme
lysyl-tRNA synthetase EC 6.1.1.6 (LysU) (Fig. 1). Previous studies
have demonstrated that compounds inhibiting enzymes in the
DAP/Lys pathways show antimicrobial effects.8–10
A recent study was conducted to screen compounds that inhibit
the DapL ortholog from A. thaliana. This study resulted in the iden-
tiﬁcation of 46 compounds with signiﬁcant IC50 values.11 Given
that DapL is a prime and attractive target for the development of
antibiotics, herbicides and algaecides, there has been signiﬁcantPeptidoglycan Biosynthesis  
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se (DapL), UDP-N-acetylmuramoyl-L-alanyl-D-glutamate:meso-2,6-diaminopimelate
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structures of DapL orthologs have been solved from A. thaliana,
Chlamydia trachomatis and Chlamydomonas reinhardtii.12–15
Here we present the ﬁrst comparative and comprehensive
screening analysis of DapL orthologs from a pathogenic bacterium
Leptospira interrogans,5 Verrucomicrobium spinosum15 and from the
alga C. reinhardtii14,15. Previously, a library of 30,000 compounds
were screened via enzymatic kinetic analyses against the A. thali-
ana DapL ortholog,11 resulting in the identiﬁcation of many small
molecule inhibitors, the majority possessing one of four main
structural moieties: hydrazide, rhodanine, barbiturate or thiobar-
biturate functionalities. The IC50 values show that the catalysis
by the orthologs is inhibited depending on the inhibitor even
though the enzymes are similar in amino acid sequence and in
quaternary structure. Together, this data has the potential to help
elucidate the mode(s)/mechanism(s) of DapL inhibition to facilitate
the discovery and or development of compounds that are classiﬁed
as antibiotics, algaecides or herbicides.
2. Materials and methods
2.1. Protein expression plasmid constructs
Descriptions of the plasmids used for protein expression
(pET30a::LidapL, pET30a::CrdapL and pET30a::VsdapL) have been
previously reported.5,14–16 The recombinant protein carry a hexa-
histidine tag at the amino terminus derived from the pET30a.
2.2. Functional complementation plasmid constructs
The plasmids used for functional complementation of the E. coli
dapD/E double mutant strain AOH1 was produced by sub-cloning
the dapL ORF or full length cDNA from pET30a::LidapL pET30a::Cr-
dapL, pET30a::VsdapL into pBAD3317 to produce the plasmids pBA-
D33::LidapL, pBAD33::CrdapL and pBAD33::VsdapL.5,14,15 The
recombinant proteins produced from the pBAD33 constructs are
identical to the protein produced from the pET30a constructs.
2.3. Functional complementation of dapD/dapE E. coli mutant
AOH1
The E. coli mutant AOH1 (DdapD::Kan2,dapE6)3 was trans-
formed with pBAD33 or pBAD33::LidapL, pBAD33::CrdapL,
pBAD33::VsdapL and grown on LB agar medium supplemented
with 50 lg mL1 L,L-DAP, 34 lg mL1 chloramphenicol and
50 lg mL1 kanamycin. Individual colonies were grown to an OD
of 0.5 at 600 nm and serially diluted from 101 to 106 using
0.85% (w/v) and replica plated onto LB medium plus 0.2% (w/v)
arabinose with or without 50 lg mL1 L,L-DAP. The cultures were
grown at 30 C for 24 h.
2.4. Heterologous expression DapL orthologs
E. coli BL21-CodonPlus-RIPL strain (Agilent Technologies., La
Jolla, CA, USA) was transformed with the following protein expres-
sion vectors pET30a::LidapL,5 pET30a::CrdapL14,15 and pET100D::
VsdapL.16 To facilitate recombinant expression of the DapL ortho-
logs, 10 mL of LB broth containing 50 lg/mL kanamycin and
34 lg/mL chloramphenicol were inoculated and grown overnight
at 37 C with constant shaking at 225 rpm. These starter cultures
were added into 1 L of LB media containing 50 lg/mL kanamycin
and 34 lg/mL chloramphenicol and grown at 37 C with constant
shaking at 225 rpm until an OD600 of 0.5 was achieved. DapL
recombinant expression was initiated by the addition of isopropyl
b-D-1-thiogalactopyranoside (IPTG) to a ﬁnal concentration of
0.5 mM at 25 C for 6 h with constant shaking at 225 rpm. Thebacterial cells were pelleted by centrifugation at 7000g at 4 C
for 20 min.
2.5. Afﬁnity puriﬁcation of DapL orthologs
For puriﬁcation, bacterial cells were thawed and re-suspended
in 30 mL of sonication buffer containing 50 mM sodium phosphate,
300 mM sodium chloride at pH 8.0. This suspension was sonicated
on ice for 4  30 s. Cellular debris was pelleted by centrifugation at
11,000g at 4 C for 30 min. The decanted supernatant was incu-
bated with 4 mL of Ni-NTA agarose resin (Qiagen, USA) and shaken
at 4 C for 45 min. Upon addition to a biological column, the
Ni-NTA agarose resin was packed at a rate of 1 mL/min, and then
washed with 3  30 mL of wash buffer containing 50 mM sodium
phosphate, 300 mM sodium chloride, 10 mM imidazole at pH 8.0
at a rate of 2 mL/min. Recombinant DapL enzymes were eluted
with 3  10 mL of elution buffer containing 50 mM sodium phos-
phate, 300 mM sodium chloride, 250 mM imidazole at pH 8.0 at
2 mL/min. Puriﬁcation of the DapL orthologs was monitored by
UV absorption at 220 nm (data not shown). All wash and elution
fractions were monitored by SDS–PAGE analysis. Fractions con-
taining His6-tagged DapL enzymes were concentrated using Ami-
con Ultra 10,000 molecular weight cutoff (MWCO) ﬁlter units by
spinning the samples at 7000g for 15 min at 4 C. Concentrated
DapL enzymes were diluted to 0.043 mg/mL (LiDapL and CrDapL)
or 0.430 mg/mL (VsDapL) and stored at 4 C in 100 mM HEPES–
KOH pH 7.6 buffer containing 20 lM pyridoxal-50-phosphate
(PLP), 2 mM ethylenediaminetetraacetic acid (EDTA pH 7.0), and
1 mM dithiothreitol (DTT). Overall yields of puriﬁed proteins were:
6.2, 20.4, and 6.6 mg/L for LiDapL, VsDapL, and CrDapL respectively.
2.6. Quantiﬁcation of puriﬁed DapL enzymes
A bicinchoninic acid assay (BCA) was used to determine protein
concentration of puriﬁed DapL preparation against a bovine serum
albumin (BSA) standard curve after buffer exchange and
concentration.
2.7. L,L-DAP aminotransferase assay of DapL orthologs
An ortho-aminobenzaldehyde (OAB) assay was employed to test
DapL activity.3 A stock solution of 10 mM 2-oxoglutarate and
2.3 mM L,L-DAP in 100 mM HEPES–KOH pH 7.6 was prepared. This
was added to solid OAB, giving a ﬁnal concentration of 8.3 mM. To
prevent polymerization of the OAB, the solution was prepared
immediately before each assay. 850 lL of this assay solution was
added to a cuvette along with 100 lL of DapL enzyme (0.043 mg/
mL for LiDapL and CrDapL, 0.430 mg/mL for VsDapL) in 100 mM
HEPES–KOH pH 7.6 containing 20 lM PLP, 2 mM EDTA, and
1 mM DTT. 50 lL of HEPES–KOH pH 7.6 buffer was added to bring
the cell up to 1 mL. The effective concentrations of each component
were: 8.5 mM 2-oxoglutarate, 2.0 mM L,L-DAP, 7.0 mM OAB, and
either 4.3 lg/mL (LiDapL, CrDapL) or 43 lg/mL (VsDapL) DapL dur-
ing the assay. Under the enzyme kinetics program in the Varian
Cary 100 Bio UV–vis spectrophotometer, the cells were multi-
zeroed and their absorbance at 440 nm was monitored over
200 min to assess L,L-DAP aminotransferase activity.
2.8. KM and kcat determination
KM and kcat parameters for DapL isoforms were assessed using
the previously described L,L-DAP aminotransferase assay at
different concentrations of L,L-DAP. Enzymatic activity was mea-
sured in 1.0 mL cells containing 100 mM HEPES–KOH (pH 7.6),
8.5 mM 2-oxoglutarate, 7.0 mM OAB, and DapL enzymes
(0.043 mg/mL of LiDapL and CrDapL, 0.430 mg/mL for VsDapL) in
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and 1 mM DTT. The concentration of L,L-DAP was varied between
0.0625 and 8.0 mM (0.0625, 0.25, 0.5, 1.0, 2.0, 4.0, 8.0 mM), moni-
toring the increase in absorbance at 440 nM every 60 s for 25 min.
Runs were conducted in triplicate for each enzyme. Absorbances
were converted to molarity using an approximated e = 316 M1
cm1 for the dihydroquinazolium chromophore at 440 nm. The ki-
netic constants were calculated by nonlinear regression analysis
using GraphPad Prism version 4.0a.
2.9. Preparation of inhibitor stock solutions
From previous inhibitor screens conducted with the A. thaliana
DapL ortholog,11 ﬁve were selected for this study. Inhibitors tested
included one representative compound from the hydrazide, rhoda-
nine, barbiturate, and thiobarbiturate classes of molecules, as well
as one thiobarbiturate compound previously exhibiting time-
dependent inhibition against the A. thaliana DapL ortholog (re-
ferred to as ‘time-dependent inhibitor’); all inhibitors are shown
in Table 1. Eight micromoles of each inhibitor was dissolved in
2 mL of dimethyl sulfoxide (DMSO), resulting in a 4 lmol/mL
(4 mM) concentration. Dilutions with DMSO afforded 2, 1, 0.5,
0.2, and 0.1 mM stock inhibitor solutions respectively. When added
to the assay cell, the ﬁnal concentrations of inhibitors examined
were 200, 100, 50, 25, 10, and 5 lM, respectively.Table 1
Inhibitors used in the DapL inhibition study
Class of inhibitor Inhibitor compound number ChemBridge ID nu
Hydrazide 1 5925714
Rhodanine 2 6523070
Barbiturate 3 6072466
Thiobarbiturate 4 6088649
Time-dependent (Thiobarbiturate) 5 60589622.10. DapL inhibition assay
The ortho-aminobenzaldehyde assay was also employed to test
DapL inhibition.3 Eight separate reaction conditions were run
simultaneously. Cell 1 contained a positive control containing the
DapL ortholog in the absence of inhibitor. Cells 2 to 7 had increas-
ing concentrations (5, 10, 25, 50, 100, 200 lM respectively) of
inhibitor in addition to enzyme and assay solution. Cell 8 served
as the negative control, in which no enzyme or inhibitor was added
to the assay solution.
To each cell, 850 lL of assay solution containing 10 mM 2-oxo-
glutarate, 8.3 mM ortho-aminobenzaldehyde, and 2.3 mM L,L-DAP
were added. 50 lL of DMSO were added to cells 1 and 8. Fifty
microlitres of inhibitor solutions dissolved in DMSO were added
to cells 2 to 7 in increasing concentrations. 100 lL of DapL enzyme
solution (0.043 mg/mL for LiDapL and CrDapL, 0.430 mg/mL for
VsDapL) in 100 mM HEPES–KOH pH 7.6 containing 20 lM PLP,
2 mM EDTA, and 1 mM DTT were added to cells 1–7, with 100 lL
of 100 mM HEPES–KOH pH 7.6 containing 2 mM EDTA and 1 mM
DTT being added to cell 8. Under the enzyme kinetics program in
the Varian Cary 100 Bio UV–vis spectrophotometer, the cells were
multi-zeroed and their absorbance at 440 nm was monitored over
200 min. After plotting the concentration of inhibitor against the
maximal absorbance at 440 nm, IC50 values were determined for
each of the inhibitors against the three DapL enzymes.mber Chemical formula Molecular weight Structure
C17H15N3O3S 341.38
C19H16NO2S2Cl 389.92
C22H17N3O5 403.39
C12H13N3O2S 263.32
C27H20N4O3S 480.54
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A sequence alignment between DapL orthologs from V. spinso-
sum (WP_009961032.1), L. interrogans (YP_002757.1), C. reinhardtii
(XP_001693061.1), A. thaliana (NP_567934.1) and C. trachomatis
(NP_219900.1) (protein accession numbers in parentheses) was
performed using the program MegAlign (DNAstar) using the clu-
stalW algorithm. A boxshade representation of the alignment
was produced using the program Mobyle@Pastuer v1.0.5 (http://
mobyle.pasteur.fr/cgi-bin/portal.py?#welcome).
2.12. Structural analysis
Homology models of the DapL orthologs from V. spinosum and L.
interrogans were generated using the Phyre2 Protein Fold Recogni-
tion Server.18 Both models were produced using the structure of
DapL from C. reinhardtii (3QGU) as the template, since this struc-
ture had the highest degree of sequence identity to the models.
In each case 97% of the residues were modeled with 100%
conﬁdence.
The ConSurf Server19–22 was used to visualize the level of con-
servation of amino acid positions within DapL based on a multiple
sequence alignment of orthologs from V. spinsosum (protein acces-
sion number WP_009961032.1), L. interrogans (YP_002757.1),
C. reinhardtii (XP_001693061.1), A. thaliana (NP_567934.1) and
C. trachomatis (NP_219900.1). The server replaced the B-factor col-
umn within the PDB ﬁle of DapL from A. thaliana (3EI7) with the
conservation scores (1 = low conservation – 9 = high conservation),
which allows visualization of conserved regions of the protein
using the program PYMOL (The PyMOL Molecular Graphics System,
Version 1.2r3pre, Schrödinger, LLC).
3. Results and discussion
3.1. The DapL orthologs from V. spinosum, C. reinhardtii and L.
interrogans are authentic and are able to functionally
complement the E. coli dapD/dapE (AOH1) mutant
The E. colimutant AOH1 is anm-DAP auxotroph owing to muta-
tions in dapD and dapE. The strain is unable to synthesize m-DAP
and Lys for PG and protein synthesis respectively. DapL is capable
of bypassing the DapD, DapC and DapE steps in the E. coli (Fig. 2A).
The AOH1 strain was transformed with either an empty plasmid
(pBAD33) or a plasmid expressing the DapL ortholog from
V. spinosum (pBAD33::VsdapL), C. reinhardtii (pBAD33::CrdapL) or
from L. interrogans (pBAD33::LidapL). The complementation analy-
sis show that AOH1 is able to grow on the DAP free medium only
when expressing functional DapL compared to the vector only
control which is not viable on the DAP free medium (Fig. 2B).
3.2. Catalytic efﬁciency and inhibitor analysis of DapL orthologs
A collection of DapL inhibitors was recently identiﬁed by
screening a chemical library for compounds that inhibit the DapL
from A. thaliana. The comparative ability of these compounds to in-
hibit DapL orthologs was examined. To perform this analysis the
ortho-aminobenzaldehyde (OAB) assay was employed using the
puriﬁed DapL orthologs (Fig. 3). This assay measures the produc-
tion of L-THDP from L,L-DAP (amino donor) and 2-oxoglutarate
(amino acceptor). The reaction product reacts with OAB to form a
chromogenic dihydroquinazolium adduct with an absorbance peak
at 440 nm.3 The KM and kcat values for each of the three enzymes
were determined and are listed in Table 2. Analysis of this data
shows that VsDapL has a lower catalytic turnover in comparison
to the other orthologs, whereas CrDapL and LiDapL have similar
catalytic efﬁciency.Next each enzyme was tested against the collection of inhibitor
compounds. LiDapL and AtDapL show similar patterns of inhibition
across the inhibitor series. In contrast, VsDapL and CrDapL show
signiﬁcant differences. Compared with LiDapL and the AtDapL,
CrDapL is insensitive to hydrazide 1 (IC50 >200 lM) and the VsDapL
is insensitive to time-dependent inhibitor 5 (no observable inhibi-
tion), while VsDapL is the most sensitive enzyme to the barbiturate
(3) and thiobarbiturate (4) containing inhibitors (IC50 5 lM)
(Table 3).
During data collection some anomalous results were obtained
when conducting inhibitor assays against VsDapL, due to its rela-
tively slower catalytic rate. While all inhibition assays conducted
gave enough data to establish a linear regression of A440nm values,
allowing us to calculate the IC50 of the inhibitor against the partic-
ular enzyme, some negative absorbance values were observed at
increasing concentrations (50–200 lM). This is likely due to inhib-
itor precipitation or decomposition and was primarily seen in the
barbiturate, thiobarbiturate, and time-dependent (3–5, respec-
tively) inhibitors in VsDapL. The lower catalytic efﬁciency of
VsDapL in comparison to the other two enzymes magniﬁes the ef-
fect of these inhibitors precipitating or decomposing at higher con-
centrations. Rhodanine inhibitor 2 gave negative absorbance
values at higher concentrations in both the CrDapL and LiDapL as-
says at 200 lM concentrations. None of these negative absorbance
values were included in the IC50 determination for the inhibitors.
Notably, negative absorbance values were not observed with the
hydrazide inhibitor on any DapL ortholog.23
3.3. Structural insights into DapL
The holoenzyme of most aminotransferases are homodimeric,
consistent with the observed oligomeric state suggested by X-ray
crystallography of the DapL orthologs from A. thaliana (AtDapL),
C. trachomatis (CtDapL) and C. reinhardtii (CrDapL)12–15 and bio-
physical studies of the C. reinhardtii (CrDapL) enzyme.14 Structural
analyses of these orthologs show that there are three interacting
motifs that determined the active site of the enzyme. To show
these motifs the DapL amino acid sequences from V. spinosum, L.
interrogans, C. reinhardtii, A. thaliana and C. trachomatis were
aligned, revealing that the three main domains are conserved
(Fig. 4). In addition, there are six other conserved amino acid resi-
dues that play a role in determining the active site of the enzyme
that are outside of the domains. They are as follows: I43, G44,
K111, Y134, N188, R390 (based on the V. spinosum numbering)
which are highlighted as red circles (Fig. 4).12,14,16 It should be
noted that aminotransferase reactions generally proceed through
two separate stages using a bimolecular ping–pong mechanism.24
In this mechanism of action, the amino donor, usually an amino
acid is converted to its cognate 2-oxo acid in three steps. The ﬁrst
step is Schiff base formation, which is facilitated by the PLP co-fac-
tor. PLP is covalently linked to a conserved Lys residue through an
imine linkage to the e-amino group of the Lys in the active site of
the enzyme. The PLP binding domain is located in loopA of the en-
zyme (Fig. 4). The second step is tautomerization followed by
hydrolysis, which is the third and ﬁnal step. In the second stage
of the mechanism, the 2-oxo acid substrate (amino acceptor) is
converted to its cognate amino acid.25
Homology models of the VsDapL and LiDapL orthologs show a
similar tertiary structure compared to the AtDapL, CrDapL and
CtDapL structures previously determined12–15 (Fig. 5A). As both
monomers contribute residues to the active site of DapL enzymes,
it is assumed that the VsDapL and LiDapL form dimers consistent
with the quaternary structure of the previously solved structures.
When the structures are superimposed it can be seen that, while
all orthologs share an overall similar structure, the CtDapL struc-
ture (the green structure in Fig. 5B), for which we do not test
B 
A 
10-1 10-2 10-3 10-4 10-5 10-6
pBAD33
pBAD33::VsdapL
pBAD33::LidapL
pBAD33::CrdapL
- L,L-DAP
DapL
DapD DapC DapE
L-THDP L,L-DAP
L-glutamate 2-ketoglutarate 
+ L,L-DAP
10-1 10-2 10-3 10-4 10-5 10-6
Figure 2. Functional complementation of the E.coli dapD/E mutant (AOH1). (A) Reaction catalyzed by DapL showing the ability of the enzyme to circumvent the DapD, DapC
and DapE steps in the E. coli acyl pathways. (B) Functional complementation of E. coli dapD/Emutant (AOH1) using the vectors expressing the DapL orthologs from V. spinosum
(pBAD33::VsdapL), Leptospira interrogans (pBAD33::LidapL) and Chlamydomonas reinhardtii (pBAD33::CrdapL).
Lane LiDapL (A) VsDapL (B) CrDapL (C)
1 MW markers MW markers MW markers
2 Media supernatant Media supernatant - 
3 Sonicated supernatant Sonicated supernatant Media supernatant
4 Flow Through Flow Through Sonicated supernatant
5 Wash 1 Wash 1 Flow Through
6 Wash 2 Wash 2 Wash 1
7 Wash 3 Wash 3 Wash 2
8 Elution 1 Elution 1 Wash 3
9 Elution 2 Elution 2 Elution 1 
10 Elution 3 - Elution 2 
A B C 
505050
252525
Figure 3. SDS–PAGE analysis of puriﬁed recombinant DapL orthologs. (A) SDS–PAGE analysis of LiDapL puriﬁcation, (B) SDS–PAGE analysis of VsDapL puriﬁcation, (C), SDS–
PAGE analysis of CrDapL puriﬁcation. The proteins were resolved on 12.5% (w/v) acrylamide gels and were stained using Coomassie blue. The table below the ﬁgure describes
the constituent of each lane as per the puriﬁcation scheme. The molecular weight (MW) markers are denoted in kDa.
Table 2
KM and kcat, and KM/kcat enzyme parameters for DapL orthologs
Enzyme LiDapL VsDapL CrDapL
KM for L,L-DAP (mM) 1.1 ± 0.2 4 ± 1 2.7 ± 0.7
kcat (s1) 5.7 1.6 16.4
KM/kcat (s1 M1) 5.2  103 0.4  103 6.1  103
528 S. M. K. McKinnie et al. / Bioorg. Med. Chem. 22 (2014) 523–530inhibitors here, has a slightly more open conformation, as pointed
out by Watanabe et al.13 The other four orthologs; AtDapL, CrDapL,
VsDapL and LiDapL share a much closer resemblance, yet they be-
have quite differently in regards to the inhibitors as shown in
Table 3.
To address the question of why these DapL orthologs show al-
tered responses to the inhibitors in Table 2, we closely examinedthe active site region of the four orthologs, focusing on differences
in sequence between these enzymes. All of the putative residues
involved in substrate binding and recognition are conserved be-
tween orthologs (those marked with red dots, Fig. 4) except for a
single E74D substitution in CtDapL (E77 VsDapL, E75 LiDapL,
E110 CrDapL and E97 AtDapL) (Fig. 4). It should be noted that
CtDapL was not one of the DapL orthologs screened in this study.13
While the residues occupy similar arrangements within the active
site (Fig. 5C), all of the structures used were solved without PLP in
the active site and Watanabe et al.26 show that considerable rear-
rangement of the active site occurs upon PLP and substrate bind-
ing. To identify residues within and around the active site that
may play a role in the altered inhibition patterns seen in DapL
orthologs (Table 3), we used the ConSurf Server, which displays
the conservation of amino acids between the enzymes (tur-
quoise-through-maroon indicates variable-through-conserved).
Table 3
Calculated IC50 values in lM of inhibitors against DapL enzymes
Inhibitor
compound
number
LiDapL
IC50 (lM)
VsDapL IC50
(lM)
CrDapL IC50
(lM)
AtDapL ⁄
IC50 (lM)
1 6.8 47 <10% Inhibition
at 200 lM
5
2 48 250 119 46
3 48 4.7 56 37
4 28 5.7 33 25
5 25 No inhibition
observed
62 33
The asterisk denotes IC50 values determined from the A. thaliana DapL orthologs 11.
S. M. K. McKinnie et al. / Bioorg. Med. Chem. 22 (2014) 523–530 529Overall the active site groove is well conserved (Fig. 5D). Figure 5E
shows the innermost shell of residues that interact with the sub-
strate analogue PLP-DAP. All of these residues are conserved be-
tween the four orthologs except for a single residue: A128
(numbering according to the A. thaliana sequence). This L-alanine
residue in the A. thaliana sequence is a L-serine in the other three
structures, however this change does not account for any of the
inhibition patterns seen in Table 3. Looking at residues slightly fur-
ther away from PLP (Fig. 5F) shows the presence of a number of
variable residues. These residues may be responsible for the
different behaviors seen regarding inhibitors particularly whenA. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
A. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
A. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
A. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
A. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
A. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
A. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
A. thaliana
L. interoggans
V. spinosum
C. trachomatis
C. reinhardtii
Figure 4. Multiple sequence alignment of DapL orthologs. The diagram depicts the three
of the active site. Conserved amino acids that play a role in active site formation are higtaking into the account the size of the inhibitors, which are much
larger than PLP and the natural substrates. It would be interesting
to discern the binding site(s) of the inhibitors using X-ray crystal-
lography as this would provide further insight into the mecha-
nisms of these inhibitors and may identify residues that could be
used to develop ortholog-speciﬁc inhibitors. This would be feasible
given the fact that the enzyme will not catalyze the inhibitors since
they are not natural substrates.
We are now considering experiments aimed at assessing the
speciﬁcity of the inhibitory compounds towards DapL. This will
be carried out by exposing these compounds to E. coli dap auxotro-
phic mutants that are expressing the DapL orthologs compared to
wild-type (WT) E. coli. If the compound(s) are speciﬁc for DapL, one
would expect that it will inhibit or hinder growth in the E. coli dap
mutants expressing the DapL orthologs and not the WT bacterium
since E. coli does not employ the DapL pathway for DAP/Lys
synthesis.
The discovery of new biocide targets are of interest to the scien-
tiﬁc community due to the origins and evolution of antibiotic resis-
tant bacteria.27 In addition, there is always a need for the
development of novel algaecides for the aquaria industry and her-
bicides for the agricultural industry. DapL is a prime and attractive
target for such biocide development or discovery given the fact
that it catalyzes a reaction that is essential for life. From a bio-
chemistry point of view, the enzyme is involved in the synthesisLoop B
Loop A
Loop C 
motifs annotated as Loop B, Loop A and Loop C which are involved in the formation
hlighted with red circles.
A 
VsDapL LiDapL CrDapL AtDapL CtDapL 
Active site 
Active site 
B D 
PLP-DAP 
C 
E F 
Figure 5. Structural analysis of DapL orthologs (A) Structures of DapL from V. spinosum, L. interrogans (homology models generated using the Phyre2 server), C. reinhardtii
(PDB id: 3QGU), A. thaliana (PDB id: 3EI7) and C. trachomatis (PDB id: 3ASA). (B) Structural comparison of DapL orthologs: L. interrogans in purple, V. spinosum in orange, A.
thaliana in blue, C. reinhardtii in yellow and C. trachomatis in green. (C) Putative active site residues as identiﬁed by red circles in the sequence alignment in Figure 4 (each
residue type is shown in a different color for clarity, ﬁgure in stereo). (D) A ConSurf analysis of DapL orthologs. A top view of DapL from A. thaliana (3EI7) is shown. The
residues are colored by their conservation grades with turquoise-through-maroon indicating variable-through-conserved amino acids. A substrate analogue PLP-DAP from
the A. thaliana DapL structure 3EI6 is shown in green to indicate the active site groove, which is highly conserved. (E) Stereo image of residues in the innermost shell
surrounding PLP-DAP. (F) Stereo image of residues in the near vicinity of PLP-DAP (i.e. the second shell of residues surrounding the active site), excluding those in the
innermost shell.
530 S. M. K. McKinnie et al. / Bioorg. Med. Chem. 22 (2014) 523–530of substrates that are necessary for both the synthesis of PG and
proteins in bacteria and photosynthetic organisms.
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